Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …

The antiangiogenic agent bevacizumab has been approved for the treatment of non–small
cell lung cancer (NSCLC), although the survival benefit associated with this agent is …

Itraconazole is an oral antifungal that has a been reported to have anticancer effect in non-
small cell lung cancer (NSCLC) through inhibition of angiogenesis. The aim is to evaluate …

Understanding cancer biology and the development of novel agents for cancer treatment
has always been the goal of cancer researchers. However, the research and development of …

Introduction Preclinical studies have suggested that the oral antifungal agent itraconazole
specifically inhibits proliferation, migration, and tube formation of endothelial cells …

Objective To report the case of a patient receiving itraconazole for the treatment of
histoplasmosis and his subsequent reduction in pancreatic tumor size. Case summary A 64 …

The repurposing of drugs is becoming increasingly attractive as it avoids the lengthy process
and cost implications associated with bringing a novel drug to market. Itraconazole is a …

Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of
clinical activity that is of interest in oncology. There is evidence that at the clinically relevant …

Purpose: Itraconazole is a triazole antifungal drug that has recently been found to inhibit
angiogenesis. Itraconazole is a relatively well-tolerated drug but shows hepatotoxicity in a …

Itraconazole (ITA), an old and widely prescribed antifungal drug with excellent safety profile,
has more recently been demonstrated to be a multitarget antiangiogenesis agent affecting …